Bezuclastinib

Pre-clinicalActive

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Systemic Mastocytoses, Indolent

Conditions

Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive

Trial Timeline

— → —

NCT ID

NCT06915766

About Bezuclastinib

Bezuclastinib is a pre-clinical stage product being developed by Cogent Biosciences for Systemic Mastocytoses, Indolent. The current trial status is active. This product is registered under clinical trial identifier NCT06915766. Target conditions include Systemic Mastocytoses, Indolent, Systemic Mastocytoses, Aggressive.

What happened to similar drugs?

10 of 20 similar drugs in Systemic Mastocytoses, Indolent were approved

Approved (10) Terminated (4) Active (7)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅BMS-986165Bristol Myers SquibbApproved

✅versus hydroxychloroquineSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06915766	Pre-clinical	Active	—	—	Systemic Mastocytoses, Indolent
NCT04996875	Phase 2	Recruiting	Nov 9, 2021	Jul 1, 2026	Advanced Systemic Mastocytosis (AdvSM)

Competing Products

20 competing products in Systemic Mastocytoses, Indolent

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29